Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence

J Allergy Clin Immunol. 2014 Oct;134(4):955-7. doi: 10.1016/j.jaci.2014.05.024. Epub 2014 Jul 2.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Pharmacological / metabolism
  • Cells, Cultured
  • Claudins / genetics
  • Claudins / metabolism
  • Clinical Protocols
  • Cyclosporine / therapeutic use*
  • Dermatitis, Atopic / drug therapy*
  • Dermatitis, Atopic / genetics
  • Follow-Up Studies
  • Genome
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interferon-gamma / metabolism
  • Leptin / genetics
  • Leptin / metabolism
  • Recurrence
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / radiation effects
  • Th2 Cells / drug effects
  • Th2 Cells / immunology
  • Th2 Cells / radiation effects
  • Transcriptome
  • Treatment Outcome
  • Ultraviolet Therapy

Substances

  • Biomarkers, Pharmacological
  • Claudins
  • Immunosuppressive Agents
  • Leptin
  • Interferon-gamma
  • Cyclosporine
  • claudin 8